Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

The New England journal of medicine - 7 Oct 2004

Liaw Yun-Fan, Sung Joseph J Y, Chow Wan Cheng, Farrell Geoffrey, Lee Cha-Ze, Yuen Hon, Tanwandee Tawesak, Tao Qi-Min, Shue Kelly, Keene Oliver N, Dixon Jonathan S, Gray D Fraser, Sabbat Jan

Abstract excerpt

BACKGROUND: The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown. METHODS: Patients with chronic hepatitis B who had histologically confirmed cirrhosis or advanced fibrosis were randomly assigned in a 2:1 ratio to receive lamivudine (100 mg per day) or placebo for a maximum of five years. Of 651 patients, 436...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Liver Cirrhosis

Share to Liver Neoplasms

Source

Identifiers

PMID: 15470215
DOI: 10.1056/NEJMoa033364

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lamivudine for patients with chronic hepatitis B and advanced liver disease.PMID 15470215Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.Semantic proximity Read ↗

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Chronic hepatitis B virus infection: treatment strategies for the next millennium.Semantic proximity Read ↗

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.Semantic proximity Read ↗

Telbivudine versus lamivudine in patients with chronic hepatitis B.Semantic proximity Read ↗

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Long‐term therapy for chronic hepatitis B : Hepatitis B virus DNA suppression leading to cirrhosis reversalSemantic proximity Read ↗

Prognosis of 153 patients with decompensated hepatitis B virus-related cirrhosis is improved after 3-year continuous lamivudine treatment.Semantic proximity Read ↗

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.